Drug Trial Radar · NCT05556343
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Jan 18, 2023
Primary completion
Aug 19, 2024
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)
Conditions
- Cardiomyopathy, Hypertrophic
Interventions
MYK-224Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Adverse Events and Serious Adverse EventsTime frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Number of Participants With at Least One Event of ArrhythmiasTime frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac ArrestTime frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Change From Baseline in Vital Signs - Heart RateTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Change From Baseline in Vital Signs - Mean Systolic Blood PressureTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood PressureTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Change From Baseline in Vital Signs - Respiratory RateTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Change From Baseline in Vital Signs - TemperatureTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Change From Baseline in Vital Signs - WeightTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Number of Participants With Abnormal Physical Examination ResultsTime frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Number of Participants With Abnormal Electrocardiogram (ECG) ResultsTime frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)Time frame: Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
- Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
Local Institution - 0026
La Jolla, California
Local Institution - 0014
Los Angeles, California
Local Institution - 0016
San Francisco, California
Local Institution - 0001
Kansas City, Kansas
Local Institution - 0032
New York, New York
Local Institution - 0013
Durham, North Carolina
Local Institution - 0031
Cincinnati, Ohio
Local Institution - 0015
Cleveland, Ohio
Local Institution - 0024
Portland, Oregon
Local Institution - 0021
Nashville, Tennessee
Local Institution - 0025
San Antonio, Texas
Local Institution - 0006
Salt Lake City, Utah
Local Institution - 0029
Milan, Italy
Local Institution - 0027
Bologna, BO, Italy
Local Institution - 0005
Florence, FI, Italy
Local Institution - 0030
Wroclaw, Poland
Local Institution - 0011
Katowice, Silesian Voivodeship, Poland
Local Institution - 0009
A Coruña, Spain
Local Institution - 0023
Barcelona, Spain
Local Institution - 0010
Majadahonda, Spain
Local Institution - 0028
Alicante, A, Spain
Local Institution - 0022
Granada, GR, Spain
Local Institution - 0008
Málaga, MA, Spain
Local Institution - 0002
El Palmar, MU, Spain
Local Institution - 0003
Valencia, V, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.